HK Stock MarketDetailed Quotes

02561 VISEN PHARMA-B

Watchlist
  • 47.600
  • -0.750-1.55%
Not Open Apr 24 16:08 CST
5.42BMarket Cap-27.56P/E (TTM)

About VISEN PHARMA-B Company

Weisheng Pharmaceutical is an innovative biomedical company focusing on endocrine-related treatment. It is committed to innovative treatments with more humane care so that endocrine patients can enjoy better treatment processes and curative effects to achieve the desired life. Weisheng puts patients' needs first and is committed to providing first-in-class (First in Class) or best-in-class (Best in Class) endocrine disease products and treatment solutions. Areas of treatment include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Weisheng continues to gather senior professionals with an international background, as well as technology and resources at the cutting edge of global innovation, to thoroughly lay out the Chinese market. It has set up offices in Shanghai, Beijing, Hong Kong, and Taipei to implement a full chain layout in the field of innovative endocrine drugs from R&D, production to sales, so that more Chinese endocrine patients can benefit from the world's cutting-edge and reliable treatment plans earlier.

Company Profile

Symbol02561
Company NameVISEN PHARMA-B
ISINKYG93Y5D1039
Listing DateMar 21, 2025
Issue Price68.80
Shares Offered11.39M share(s)
FoundedNov 1, 2018
Registered AddressCayman Islands
ChairmanMichael Wolff JENSEN
Secretaryshiting chen
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeHarbour Place 2nd Floor PO Box 472 103 South Church Street Grand Cayman KY1-1106 Cayman Islands
Head Office and Principal Place of BusinessRoom 1919, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees52
MarketHong Kong motherboard
Emailinfo@visenpharma.com
Business Weisheng Pharmaceutical is an investment holding company mainly engaged in the development and commercialization of disruptive endocrine therapies. The company's main products under development include somatotropin, navir peptides, and paropetriparatide. Somatropin is used to treat growth hormone deficiency patients in children aged 3 to 17 years. Navirpeptide is a disease-repair treatment for children aged 2 to 10 with achondroplasia. Paropetriparatide is a treatment used to treat hypoparathyroidism in adults. The company is in the advanced stages of research and development, and the products are close to commercialization.

Company Executives

  • Name
  • Position
  • Salary
  • Michael Wolff JENSEN
  • Chairman of the Board, Non-executive Directors, Chairman of the Nomination Committee
  • --
  • Jan Moller MIKKELSEN
  • Non-executive Directors
  • --
  • shan fu
  • Non-executive Directors, Audit Committee Members
  • --
  • anbang lu
  • CEOs, Executive Director, Remuneration Committee Members, Authorized Representative
  • --
  • Michael J. CHANG
  • Non-executive Directors
  • --
  • yibo cao
  • Non-executive Directors
  • --
  • YAO Zhengbin (Bing)
  • Independent Non-Executive Director, Nomination Committee Members, Audit Committee Members
  • --
  • bingjun chen
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members
  • --
  • hong ni
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
  • --
  • jun chen
  • Chief Commercial Officer
  • --
  • jian wu
  • Executive Advisors
  • --
  • shiting chen
  • Authorized Representative, Company Secretary
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More